lepodisiran
Jump to navigation
Jump to search
Indications
- investigation treatment of elevated serum lipoprotein(a) cholesterol
Dosage
- 4 mg to 608 mg SC
Mechanism of action
- dose-dependent, long-duration reductions in serum lipoprotein(a) cholesterol
More general terms
References
- ↑ Nissen SE, Linnebjerg H, Shen X et al Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a). A Randomized Dose-Ascending Clinical Trial. JAMA. Published online November 12, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37952254 PMCID: PMC10641766 (available on 2024-05-12) https://jamanetwork.com/journals/jama/fullarticle/2811935